Literature DB >> 18923728

The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-resistant TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada.

Paul E Alexander1, Prithwish De.   

Abstract

Resistance to anti-tuberculosis (TB) drugs continues to present a major challenge to global public health. Resistance usually develops due to inadequate TB management, including improper use of medications, improper treatment regimens and failure to complete the treatment course. This may be due to an erratic supply or a lack of access to treatment, as well as to patient noncompliance. However, the emergence and transmission of drug-resistant TB, including the recently detected extensively drug resistant TB (XDR-TB), is driven, in part, by the synergistic relationship between TB and HIV (TB/HIV coinfection). There is evidence that persons infected with HIV are more likely to experience XDR-TB. XDR-TB is virtually untreatable with available TB medications. XDR-TB presents a grave global public health threat, particularly in high HIV prevalence settings. The present commentary discusses the current status of XDR-TB and draws attention to the urgency in addressing this problem, for both the global and Canadian public health networks. XDR-TB and the apparent XDR-TB and HIV association warrants further study.

Entities:  

Keywords:  Coinfection; Drug resistance; HIV; MDR-TB; TB; Tuberculosis; XDR-TB

Year:  2007        PMID: 18923728      PMCID: PMC2533560          DOI: 10.1155/2007/986794

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  17 in total

1.  Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran.

Authors:  Mohamad Reza Masjedi; Parissa Farnia; Setara Sorooch; Majid Valiollah Pooramiri; Seyed Davood Mansoori; Abolhasan Zia Zarifi; Ali Akbarvelayati; Sven Hoffner
Journal:  Clin Infect Dis       Date:  2006-08-21       Impact factor: 9.079

2.  Extensively drug resistant tuberculosis: beware patients lost to follow-up.

Authors:  Ulf R Dahle
Journal:  BMJ       Date:  2006-09-30

3.  XDR tuberculosis--implications for global public health.

Authors:  Mario C Raviglione; Ian M Smith
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

4.  Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2006-03-24       Impact factor: 17.586

Review 5.  Tuberculosis and HIV: current status in Africa.

Authors:  M C Raviglione; A D Harries; R Msiska; D Wilkinson; P Nunn
Journal:  AIDS       Date:  1997       Impact factor: 4.177

Review 6.  Can we get more HIV-positive tuberculosis patients on antiretroviral treatment in a rural district of Malawi?

Authors:  R Zachariah; R Teck; O Ascurra; P Gomani; M Manzi; P Humblet; P Nunn; F M L Salaniponi; A D Harries
Journal:  Int J Tuberc Lung Dis       Date:  2005-03       Impact factor: 2.373

7.  Tuberculosis in Calgary, Canada, 1995-2002: site of disease and drug susceptibility.

Authors:  H Yang; S K Field; D A Fisher; R L Cowie
Journal:  Int J Tuberc Lung Dis       Date:  2005-03       Impact factor: 2.373

8.  Impact of HIV on tuberculosis in sub-Saharan Africa: a regional perspective.

Authors:  M F Cantwell; N J Binkin
Journal:  Int J Tuberc Lung Dis       Date:  1997-06       Impact factor: 2.373

9.  Human immunodeficiency virus-related tuberculosis and primary drug resistance in Bangkok, Thailand.

Authors:  J Punnotok; N Shaffer; T Naiwatanakul; U Pumprueg; P Subhannachart; A Ittiravivongs; C Chuchotthaworn; P Ponglertnapagorn; N Chantharojwong; N L Young; K Limpakarnjanarat; T D Mastro
Journal:  Int J Tuberc Lung Dis       Date:  2000-06       Impact factor: 2.373

Review 10.  Zoonotic tuberculosis due to Mycobacterium bovis in developing countries.

Authors:  O Cosivi; J M Grange; C J Daborn; M C Raviglione; T Fujikura; D Cousins; R A Robinson; H F Huchzermeyer; I de Kantor; F X Meslin
Journal:  Emerg Infect Dis       Date:  1998 Jan-Mar       Impact factor: 6.883

View more
  12 in total

Review 1.  Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems.

Authors:  Daniélle van Staden; Richard K Haynes; Joe M Viljoen
Journal:  Antibiotics (Basel)       Date:  2022-06-15

2.  HIV/TB co-infection in mainland China: a meta-analysis.

Authors:  Lei Gao; Feng Zhou; Xiangwei Li; Qi Jin
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

3.  Emergence of potential superbug mycobacterium tuberculosis, lessons from new delhi mutant-1 bacterial strains.

Authors:  Taha Nazir; Suraj Abraham; Azharul Islam
Journal:  Int J Health Sci (Qassim)       Date:  2012-01

4.  A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen.

Authors:  Chirajyoti Deb; Chang-Muk Lee; Vinod S Dubey; Jaiyanth Daniel; Bassam Abomoelak; Tatiana D Sirakova; Santosh Pawar; Linda Rogers; Pappachan E Kolattukudy
Journal:  PLoS One       Date:  2009-06-29       Impact factor: 3.240

5.  Genetic-and-Epigenetic Interspecies Networks for Cross-Talk Mechanisms in Human Macrophages and Dendritic Cells during MTB Infection.

Authors:  Cheng-Wei Li; Yun-Lin Lee; Bor-Sen Chen
Journal:  Front Cell Infect Microbiol       Date:  2016-10-18       Impact factor: 5.293

6.  Gallium nanoparticles facilitate phagosome maturation and inhibit growth of virulent Mycobacterium tuberculosis in macrophages.

Authors:  Seoung-Ryoung Choi; Bradley E Britigan; David M Moran; Prabagaran Narayanasamy
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

7.  Molecular clustering of patients with Mycobacterium tuberculosis strains cultured from the diabetic and non-diabetic newly diagnosed TB positive cases.

Authors:  Josephine W Mburu; Leonard Kingwara; Magiri Esther; Nyerere Andrew
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2018-06-13

8.  Prevalence and incidence rate of tuberculosis among HIV-infected patients enrolled in HIV care, treatment, and support program in mainland Tanzania.

Authors:  M Majigo; G Somi; A Joachim; J Manyahi; J Nondi; V Sambu; A Rwebembera; N Makyao; A Ramadhani; W Maokola; J Todd; M I Matee
Journal:  Trop Med Health       Date:  2020-09-04

9.  Formulation development and optimization of Lamivudine 300 mg and Tenofovir Disoproxil Fumarate (TDF) 300 mg FDC tablets by D-optimal mixture design.

Authors:  Prosper Tibalinda; Joseph Sempombe; Raphael Shedafa; Nelson Masota; Dickson Pius; Mary Temu; Eliangiringa Kaale
Journal:  Heliyon       Date:  2016-12-02

10.  The twin epidemics: Prevalence of TB/HIV co-infection and its associated factors in Ethiopia; A systematic review and meta-analysis.

Authors:  Bekele Tesfaye; Animut Alebel; Alemu Gebrie; Abriham Zegeye; Cheru Tesema; Bekalu Kassie
Journal:  PLoS One       Date:  2018-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.